Literature DB >> 4007418

Abnormalities in tests of copper metabolism in primary sclerosing cholangitis.

J B Gross, J Ludwig, R H Wiesner, J T McCall, N F LaRusso.   

Abstract

Primary sclerosing cholangitis is a chronic, cholestatic syndrome characterized by fibrosing inflammation of the bile ducts that may lead to cirrhosis and death from liver failure. Previous reports have suggested abnormal hepatic copper metabolism in this disease. Therefore, in 70 patients, we prospectively determined the levels of hepatic copper, serum copper, and serum ceruloplasmin, and the rate of urinary copper excretion to assess the diagnostic and prognostic usefulness of these tests. Virtually all patients had at least one abnormal copper test. Hepatic copper levels were elevated in 87% of patients [292 +/- 38 micrograms/g dry wt (mean +/- SE)] and 24-h urinary copper levels in 64% of patients [135 +/- 15 micrograms/24 h (mean +/- SE)] to values comparable to those seen in Wilson's disease or primary biliary cirrhosis. In advanced histologic stages of primary sclerosing cholangitis, progressively higher mean levels of hepatic and urinary copper were found. In the liver, mean copper content (in micrograms per gram dry weight) in disease stages I and II was 147 +/- 36 (mean +/- SE); in stage III (fibrosis), 302 +/- 68; and in stage IV (cirrhosis), 379 +/- 69. In the urine, mean copper excretion (in micrograms per 24 h) in stages I and II was 72 +/- 14 (mean +/- SE); in stage III, 100 +/- 14; and in stage IV, 207 +/- 30. Higher hepatic and urinary copper levels at initial evaluation were associated with decreased survival during a median follow-up period of 2.6 yr: patients with hepatic copper greater than 250 micrograms/g dry wt and urinary copper excretion greater than 200 micrograms/24 h at initial evaluation had an 18-mo survival of less than 60%. We conclude that abnormal copper metabolism is a universal feature of primary sclerosing cholangitis, that hepatic copper accumulates and urinary copper excretion increases as the disease progresses, and that the hepatic copper concentration and the 24-h urinary copper determination are useful prognostic indicators in this disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4007418     DOI: 10.1016/0016-5085(85)90326-9

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  20 in total

Review 1.  Management of primary sclerosing cholangitis: conventions and controversies.

Authors:  Natasha Chandok; Gideon M Hirschfield
Journal:  Can J Gastroenterol       Date:  2012-05       Impact factor: 3.522

2.  Cholestatic liver disease masquerading as Wilson disease.

Authors:  Vikrant Sood; Dinesh Rawat; Rajeev Khanna; Seema Alam
Journal:  Indian J Gastroenterol       Date:  2015-05-05

3.  Patients, cells, and organelles: the intersection of science and serendipity.

Authors:  Nicholas F Larusso
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

Review 4.  The immunology of primary sclerosing cholangitis.

Authors:  R W Chapman
Journal:  Springer Semin Immunopathol       Date:  1990

5.  Biliary copper excretion by hepatocyte lysosomes in the rat. Major excretory pathway in experimental copper overload.

Authors:  J B Gross; B M Myers; L J Kost; S M Kuntz; N F LaRusso
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

6.  Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience.

Authors:  J A Goss; C R Shackleton; D G Farmer; W S Arnaout; P Seu; J S Markowitz; P Martin; R J Stribling; L I Goldstein; R W Busuttil
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

Review 7.  A review and current perspective on Wilson disease.

Authors:  Mallikarjun Patil; Keyur A Sheth; Adarsh C Krishnamurthy; Harshad Devarbhavi
Journal:  J Clin Exp Hepatol       Date:  2013-07-06

Review 8.  Primary sclerosing cholangitis.

Authors:  Y Ueno; N F LaRusso
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

9.  Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis.

Authors:  K M Abu-Elmagd; M Malinchoc; E R Dickson; J J Fung; P A Murtaugh; A L Langworthy; A J Demetris; R A Krom; D H Van Thiel; T E Starzl
Journal:  Surg Gynecol Obstet       Date:  1993-10

Review 10.  Wilson disease.

Authors:  Cord Langner; Helmut Denk
Journal:  Virchows Arch       Date:  2004-06-17       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.